All articles by Lopamudra Roy

Teva to sell assets in global women’s health business for $1.38bn

Teva Pharmaceutical Industries has entered two agreements to divest the remaining stake in its specialist global women’s health business for…
Gates Foundation supports development of Immunocore’s therapeutics for infectious diseases

Immunocore has secured up to $40m in investment from Bill & Melinda Gates Foundation to boost the development of soluble…
NUS study shows Artemisinin-ALA co-treatment could destroy cancer cells

A new study conducted by researchers from the National University of Singapore (NUS) has revealed that the co-treatment using artemisinin…
GSK and Innoviva receive positive opinion from CHMP for Trelegy Ellipta to treat COPD

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for marketing…
Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs

Bristol-Myers Squibb has entered a global collaboration and licence agreement to use Halozyme Therapeutics’ Enhanze drug-delivery technology for the development…

Evotec and MaRS Innovation launch new drug-discovery partnership

German company Evotec and Canada-based MaRS Innovation (MI) have launched a joint partnership ‘LAB150’ in Toronto, Ontario, Canada.The five-year partnership…
Fujifilm opens new cell culture process development laboratories in UK

Fujifilm Diosynth Biotechnologies has opened new and advanced 10,000ft² cell culture process development laboratories in Wilton Centre, Teesside, UK.The company…
Monopar receives licence to develop Onxeo’s Validive oral mucositis treatment

Onxeo has granted a global exclusive licence to Monopar Therapeutics for its Validive (clonidine mucoadhesive buccal) tablet used to treat…
US FDA advisory committee votes for GSK’s Shingrix to prevent shingles

The US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted unanimously for GlaxoSmithKline’s…
Janssen to stop further development of JNJ-4178 hepatitis C treatment

Janssen Sciences Ireland has taken a strategic decision to discontinue further development of its investigational regimen JNJ-4178 for the treatment…